When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Dulaglutide - Wikipedia

   en.wikipedia.org/wiki/Dulaglutide

   Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

3. Eli Lilly and Company - Wikipedia

   en.wikipedia.org/wiki/Eli_Lilly_and_Company

   The company's primary revenue drivers are the diabetes drugs Humalog (insulin lispro) (1996) and Trulicity (dulaglutide) (2014). [12] Lilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk, and insulin.

4. Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?

   www.aol.com/diabetes-drugs-really-safe-reliable...

   Dulaglutide is another GLP-1 injection available under the brand name Trulicity®. This medication is FDA-approved for type 2 diabetes but is sometimes prescribed off-label for weight loss.

5. Ozempic, Trulicity among Medicare's priciest drugs ... - AOL

   www.aol.com/news/ozempic-trulicity-among-medic...

   Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday. The ...

6. Sales of Eli Lilly diabetes drug Trulicity fall short, shares ...

   www.aol.com/news/eli-lilly-reports-9-rise...

   Trulicity sales rose 24% to $1.01 billion, short of Wall Street expectations of $1.08 billion, according to Refinitiv data. Sales of Eli Lilly diabetes drug Trulicity fall short, shares drop Skip ...

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   [62] [63] [64] In 2002, Eli Lilly entered into an alliance with Amylin to further develop exenatide and secure official approval to market the drug. [65] Exenatide's 2005 approval by the U.S. Food and Drug Administration [ 66 ] was a landmark event that proved that targeting the GLP-1 receptor was a viable strategy and inspired other ...